Hostname: page-component-6766d58669-rxg44 Total loading time: 0 Render date: 2026-05-18T18:13:51.222Z Has data issue: false hasContentIssue false
  • English
  • Français

18F-Fluorodeoxyglucose uptake in different histological subtypes of nasopharyngeal carcinoma

Published online by Cambridge University Press:  10 October 2008

M-C Chang ,
S-C Tsai  and
W-Y Lin
M-C Chang
Affiliation:
Department of Nuclear Medicine, Changhua Christian Hospital, Taiwan
S-C Tsai
Affiliation:
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan
W-Y Lin*
Affiliation:
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan Institute of Biomedical Engineering, National Chung-Hsing University, Taiwan
*
Address for correspondence: Dr Wan-Yu Lin, Department of Nuclear Medicine, Taichung Veterans General Hospital, 160 Taichung Harbor Road, Section 3, Taichung 40705, Taiwan. Fax: (886) 4 23741348 E-mail: wylin@vghtc.gov.tw
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

The study aimed to delineate the relationship between 18F-fluorodeoxyglucose uptake and histological findings in nasopharyngeal carcinoma.

Methods:

We conducted a retrospective review of 88 patients referred to our positron emission tomography department with newly diagnosed, biopsy-proved nasopharyngeal carcinoma. Hospital records were reviewed for demographic and clinical data, including age, gender, body weight, histological analysis and clinical tumour stage.

Results:

Nineteen out of the 88 patients (22 per cent) had nasopharyngeal carcinoma of World Health Organization type I, 39 (44 per cent) had type II and 30 (34 per cent) had type III. The mean standardised uptake value for the primary tumour was 9.4 ± 5.0, ranging from 2.2 to 27.1. The mean standardised uptake values were 8.0 ± 3.9 for type I tumours, 9.7 ± 4.4 for type II tumours and 10.1 ± 6.3 for type III tumours (p = 0.451).

Conclusions:

Our study found that type III nasopharyngeal carcinoma exhibited a higher 18F-fluorodeoxyglucose uptake than either type II or type I nasopharyngeal carcinoma. However, this difference was not statistically significant.

Keywords

Nasopharyngeal NeoplasmsFluorodeoxyglucosePositron-Emission TomographyHistologic Type

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 6 , June 2009 , pp. 656 - 661
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Kao, CH, Shiau, YC, Shen, YY, Yen, RF. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99 m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 2002;94:1981–6CrossRefGoogle ScholarPubMed
2 Tsai, MH, Shiau, YC, Kao, CH, Shen, YY, Lin, CC, Lee, CC. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 2002;128:279–82Google ScholarPubMed
3 Yen, RF, Hung, RL, Pan, MH, Wang, YH, Huang, KM, Lui, LT et al. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003;98:283–7CrossRefGoogle ScholarPubMed
4 Ng, SH, Joseph, CT, Chan, SC, Ko, SF, Wang, HM, Liao, CT et al. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 2004;45:1669–76Google ScholarPubMed
5 Chan, SC, Ng, SH, Chang, JT, Lin, CY, Chen, YC, Chang, YC et al. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2006;33:1032–40CrossRefGoogle ScholarPubMed
6 Ng, SH, Chang, JT, Chan, SC, Ko, SF, Wang, HM, Liao, CT et al. Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging 2004;31:1073–80CrossRefGoogle ScholarPubMed
7 Chang, JT, Chan, SC, Yen, TC, Liao, CT, Lin, CY, Lin, KJ et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005;62:501–7CrossRefGoogle ScholarPubMed
8 Yen, TC, Chang, JT, Ng, SH, Chang, YC, Chan, SC, Lin, KJ et al. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 2005;46:405–10Google ScholarPubMed
9 Liu, FY, Lin, CY, Chang, JT, Ng, SH, Chin, SC, Wang, HM et al. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med 2007;48:1614–19CrossRefGoogle ScholarPubMed
10 Yen, RF, Chen, TH, Ting, LL, Tzen, KY, Pan, MH, Hong, RL. Early restaging whole-body (18)F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1152–9CrossRefGoogle ScholarPubMed
11 Chan, SC, Yen, TC, Ng, SH, Lin, CY, Wang, HM, Liao, CT et al. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. J Nucl Med 2006;47:1447–54Google ScholarPubMed
12 Nieweg, OE, Pruim, J, van Ginkel, RJ, Hoekstra, HJ, Paans, AM, Molenaar, WM et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257–61Google ScholarPubMed
13 Eary, JF, Conrad, EU, Bruckner, JD, Folpe, A, Hunt, KJ, Mankoff, DA et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1215–20Google ScholarPubMed
14 Folpe, AL, Lyles, RH, Sprouse, JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279–87Google ScholarPubMed
15 Ioannidis, JP, Lau, J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717–24Google ScholarPubMed
16 Bastiaannet, E, Groen, H, Jager, PL, Cobben, DC, van der Graaf, WT, Vaalburg, W et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83–101CrossRefGoogle ScholarPubMed
17 Lee, JD, Yang, WI, Park, YN, Kim, KS, Choi, JS, Yun, M et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005;46:1753–9Google ScholarPubMed
18 Shanmugaratnam, K, Sobin, LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993;71:2689–973.0.CO;2-H>CrossRefGoogle Scholar
19 Perez, CA, Devineni, VR, Marcial Vega, V, Marks, JE, Simpson, JR, Kucik, N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271–80CrossRefGoogle ScholarPubMed
20 Jeyakumar, A, Brickman, TM, Jeyakumar, A, Doerr, T. Review of nasopharyngeal carcinoma. Ear Nose Throat J 2006;85:168–70, 72–3, 84CrossRefGoogle ScholarPubMed
21 Yen, TC, Chang, YC, Chan, SC, Chang, JT, Hsu, CH, Lin, KJ et al. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging 2005;32:541–8CrossRefGoogle ScholarPubMed
22 Chen, YK, Su, CT, Chi, KH, Cheng, RH, Wang, SC, Hsu, CH. Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx. J Nucl Med 2007;48:8–14Google ScholarPubMed
23 Lapela, M, Leskinen, S, Minn, HR, Lindholm, P, Klemi, PJ, Soderstrom, KO et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522–7CrossRefGoogle ScholarPubMed
24 Schoder, H, Noy, A, Gonen, M, Weng, L, Green, D, Erdi, YE et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643–51CrossRefGoogle ScholarPubMed
25 Wong, CY, Thie, J, Parling Lynch, KJ, Zakalik, D, Margolis, JH, Gaskill, M et al. Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 2005;46:1659–63Google ScholarPubMed
26 Eubank, WB, Mankoff, DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84–99CrossRefGoogle ScholarPubMed
27 Mavi, A, Urhan, M, Yu, JQ, Zhuang, H, Houseni, M, Cermik, TF et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440–6Google ScholarPubMed
28 Crippa, F, Seregni, E, Agresti, R, Chiesa, C, Pascali, C, Bogni, A et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429–34CrossRefGoogle ScholarPubMed
29 Kurokawa, T, Yoshida, Y, Kawahara, K, Tsuchida, T, Okazawa, H, Fujibayashi, Y et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004;109:926–32CrossRefGoogle ScholarPubMed
30 Brenner, W, Conrad, EU, Eary, JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004;31:189–95CrossRefGoogle ScholarPubMed
31 Tateishi, U, Yamaguchi, U, Seki, K, Terauchi, T, Arai, Y, Hasegawa, T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683–91CrossRefGoogle ScholarPubMed
32 de Geus Oei, LF, van Krieken, JH, Aliredjo, RP, Krabbe, PF, Frielink, C, Verhagen, AF et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79–87CrossRefGoogle ScholarPubMed
33 Torizuka, T, Tamaki, N, Inokuma, T, Magata, Y, Sasayama, S, Yonekura, Y et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811–17Google ScholarPubMed
34 Higashi, K, Ueda, Y, Sakurai, A, Wang, XM, Xu, L, Murakami, M et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27:1778–85CrossRefGoogle ScholarPubMed
35 Mamede, M, Higashi, T, Kitaichi, M, Ishizu, K, Ishimori, T, Nakamoto, Y et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369–79CrossRefGoogle ScholarPubMed
36 Tohma, T, Okazumi, S, Makino, H, Cho, A, Mochiduki, R, Shuto, K et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 2005;52:486–90Google ScholarPubMed
37 Gu, J, Yamamoto, H, Fukunaga, H, Danno, K, Takemasa, I, Ikeda, M et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006;51:2198–205CrossRefGoogle ScholarPubMed